Switch theme
Sign up to access all valuation multiples
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
2012
332
LTM Revenue $300M
LTM EBITDA -$3.9M
$655M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Evolus has a last 12-month revenue (LTM) of $300M and a last 12-month EBITDA of -$3.9M.
In the most recent fiscal year, Evolus achieved revenue of $266M and an EBITDA of -$25.0M.
Evolus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Evolus valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $300M | XXX | $266M | XXX | XXX | XXX |
| Gross Profit | $209M | XXX | $182M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | -$3.9M | XXX | -$25.0M | XXX | XXX | XXX |
| EBITDA Margin | -1% | XXX | -9% | XXX | XXX | XXX |
| EBIT | $4.6M | XXX | -$27.2M | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | -10% | XXX | XXX | XXX |
| Net Profit | -$45.5M | XXX | -$50.4M | XXX | XXX | XXX |
| Net Margin | -15% | XXX | -19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $34.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Evolus's stock price is $9.
Evolus has current market cap of $593M, and EV of $655M.
See Evolus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $655M | $593M | XXX | XXX | XXX | XXX | $-0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Evolus has market cap of $593M and EV of $655M.
Evolus's trades at 2.5x EV/Revenue multiple, and -26.2x EV/EBITDA.
Equity research analysts estimate Evolus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Evolus has a P/E ratio of -13.0x.
See valuation multiples for Evolus and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $593M | XXX | $593M | XXX | XXX | XXX |
| EV (current) | $655M | XXX | $655M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | -166.6x | XXX | -26.2x | XXX | XXX | XXX |
| EV/EBIT | 143.2x | XXX | -24.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.0x | XXX | -11.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -28.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEvolus's last 12 month revenue growth is 32%
Evolus's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.6M for the same period.
Evolus's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Evolus's rule of X is 79% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Evolus and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | -1% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Growth | -429% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 11% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 79% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 79% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Evolus acquired XXX companies to date.
Last acquisition by Evolus was XXXXXXXX, XXXXX XXXXX XXXXXX . Evolus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Evolus founded? | Evolus was founded in 2012. |
| Where is Evolus headquartered? | Evolus is headquartered in United States of America. |
| How many employees does Evolus have? | As of today, Evolus has 332 employees. |
| Who is the CEO of Evolus? | Evolus's CEO is Mr. David Moatazedi. |
| Is Evolus publicy listed? | Yes, Evolus is a public company listed on NAS. |
| What is the stock symbol of Evolus? | Evolus trades under EOLS ticker. |
| When did Evolus go public? | Evolus went public in 2018. |
| Who are competitors of Evolus? | Similar companies to Evolus include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Evolus? | Evolus's current market cap is $593M |
| What is the current revenue of Evolus? | Evolus's last 12 months revenue is $300M. |
| What is the current revenue growth of Evolus? | Evolus revenue growth (NTM/LTM) is 32%. |
| What is the current EV/Revenue multiple of Evolus? | Current revenue multiple of Evolus is 2.2x. |
| Is Evolus profitable? | Yes, Evolus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Evolus? | Evolus's last 12 months EBITDA is -$3.9M. |
| What is Evolus's EBITDA margin? | Evolus's last 12 months EBITDA margin is -1%. |
| What is the current EV/EBITDA multiple of Evolus? | Current EBITDA multiple of Evolus is -166.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
